Results from the Nationwide Administrative Database in Japan concerning adults diagnosed with septic shock and requiring noradrenaline support during the period 2016-2019 have been published in the Blood Purification journal by Fujimori and co-workers.
Polymyxin B hemoperfusion experience from critically ill COVID-19 patients with endotoxic shock has been published recently in Artificial Organs. The study refers to 12 COVID-19 patients hospitalized in ICU who developed a secondary infection – endotexemia leading to septic shock status and whose data were collected in the observational study EUPHAS 2 from February to May 2020, showing very interesting results.
Over the last year, various works in literature have revealed the potential role of Polymyxin B Hemoperfusion in the management of non-responsive COVID-19 patients admitted to intensive care. We report here various case reports that have been presented as abstracts at international congresses and/or published in peer-reviewed journals on the use of Polymyxin B hemoperfusion in COVID-19 patients.
Interesting findings and new data on endotoxemia, endotoxic shock, implications in COVID-19 disease, role of Polymyxin B hemoperfusion and new approaches in septic AKI, were presented during the 38th International Vicenza Course on AKI and CRRT organized by Prof. Ronco which took place virtually from November 2-6 , 2020.
New perspectives in sepsis, particularly in septic AKI, and the role of the dialysis membrane were recently presented by Giuseppe Castellano at the national congress of SIN (Italian Society of Nephrology).
Exiting new results show the capability of a new PMMA membrane for continuous therapies of inhibiting complement system activation in LPS-induced AKI and lowering the transition from AKI to CKD damage, opening a new scenario in the management of septic AKI.
